The company states that its chronic pain formulation are substantially free of delta-9-tetrahydrocannabinol(TCH), which minimizes its potential for abuse. It’s a long way from a patent application to clinical trials and any data showing efficacy or safety of treatments for chronic pain. The current drug delivery effort were accelerated through the combination of proprietary in silico prediction approach, high throughput screening techniques using cell based models. The current patent application covers myrecene containing complex mixtures capable targetting the non- traditional cannabinoid receptor, TRPV1. This latest patent application complements the issued TRPV1 patent that GB Sciences licensed for Makai Biotechnology.
Many cannabis researchers have theorised that the role of terpenes in cannabis based therapies is to act as so called ‘Entourage’ components. We show that the TRPV1 receptors is a target for entourage compound, a molecular interaction that had previously been demonstrated for several of the cannabinoids. They have demonstrated that beta-mycrene is the most significant of several terpenes derived from cannabis plant that are capable of activating TRPV1 receptors. Mycrene like capsaicin causes TRPV1desenitization after prolonged exposure and should therefore prove useful in treatment of chronic pain. In creating our novel MCCM mixture for pain, we have also demonstrated that other terpenes cannabinoids present in complex mixture including those that do not demonstrate significant TRPV1 agonist activity on their own, act in combination to increase the efficacy of mycrene.
“These new chronic pain and heart formulas adhere to GB Science’s strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC. Instead, the purified THC is sold as a certified raw ingredient or used in co-branded dispensary products,” said John Poss, Chairman and CEO of the company.